{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:38:30Z","timestamp":1783021110359,"version":"3.54.6"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23HA1005"],"award-info":[{"award-number":["23HA1005"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijid.2025.108268","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T04:47:28Z","timestamp":1764391648000},"page":"108268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survival analysis of drug effectiveness of remdesivir and dexamethasone for confirmed COVID-19 patients using Japanese medical claim data"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5827-5475","authenticated-orcid":false,"given":"Shingo","family":"Mitsushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyosu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108268_bib0001","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort","volume":"75","author":"Mozaffari","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108268_bib0002","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108268_bib0003","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108268_bib0004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108268_bib0005","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-Barrier): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2025.108268_bib0006","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108268_bib0007","doi-asserted-by":"crossref","first-page":"398","DOI":"10.12688\/f1000research.131102.2","article-title":"Drug effectiveness for COVID-19 inpatients inferred from Japanese medical claim data using propensity score matching","volume":"12","author":"Mitsushima","year":"2024","journal-title":"F1000Res"},{"key":"10.1016\/j.ijid.2025.108268_bib0008","article-title":"Effectiveness of drugs for COVID-19 inpatients in Japanese medical claim data as average treatment effects with inverse probability weighted regression adjustment: retrospective observational study","author":"Mitsushima","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.ijid.2025.108268_bib0009","first-page":"01","article-title":"Drug effectiveness for COVID-19 by average treatment effects with multiple choice using medical claim data of the largest hospital network in Japan: retrospective study","volume":"7","author":"Mitsushima","year":"2023","journal-title":"J Health Sci Dev"},{"key":"10.1016\/j.ijid.2025.108268_bib0010","unstructured":"Ministry of Health, Labour and Welfare. Survey of medical institutions, https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/iryosd\/20a\/. 2025 [accessed 20 January 2025]."},{"key":"10.1016\/j.ijid.2025.108268_bib0011","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2147\/CLEP.S359072","article-title":"Existing data sources for clinical epidemiology: database of the national hospital organization in Japan","volume":"14","author":"Kanazawa","year":"2022","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ijid.2025.108268_bib0012","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.7326\/M21-0857","article-title":"Use of hydroxychloroquine, remdesivir, and dexamethasone among adults hospitalized with COVID-19 in the United States: a retrospective cohort study","volume":"174","author":"Mehta","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2025.108268_bib0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.15585\/mmwr.mm7303a2","article-title":"Underuse of antiviral drugs to prevent progression to severe COVID-19 \u2013 Veterans Health Administration, March-September 2022","volume":"73","author":"Monach","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijid.2025.108268_bib0014","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.3390\/ijerph182010929","article-title":"Survival analysis of symptomatic COVID-19 in Phuentsholing Municipality, Bhutan","volume":"18","author":"Gyeltshen","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijid.2025.108268_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.969251","article-title":"Survival analysis and mortality predictors of COVID-19 in a pediatric cohort in Mexico","volume":"10","author":"Sol\u00f3rzano-Santos","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijid.2025.108268_bib0016","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12879-023-08129-8","article-title":"A survival analysis of socio-demographic and clinical predictors among hospitalized COVID-19 patients in Southern Iran","volume":"23","author":"Esfandiari","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108268_bib0017","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12916-022-02364-7","article-title":"Survival among people hospitalized with COVID-19 in Switzerland: a nationwide population-based analysis","volume":"20","author":"Anderegg","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.ijid.2025.108268_bib0018","unstructured":"Ministry of Health, Labour and Welfare. Guideline of the medical treatment for COVID-19 patients, https:\/\/www.mhlw.go.jp\/content\/001248424.pdf [in Japanese] 2023 [accessed 07 February 2025]."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:48:02Z","timestamp":1783018082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225004904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":18,"alternative-id":["S1201971225004904"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108268","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival analysis of drug effectiveness of remdesivir and dexamethasone for confirmed COVID-19 patients using Japanese medical claim data","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108268"}}